Can a common gout pill ease the aftermath of a blood clot?
NCT ID NCT06440694
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study is testing whether a low dose of colchicine, a drug usually used for gout, can reduce the risk of post-thrombotic syndrome (PTS) after a deep vein thrombosis (DVT) in the leg. PTS can cause chronic pain, swelling, and skin changes. The trial will enroll 150 adults with a first DVT, giving them either colchicine or a placebo daily for 180 days. The main goal is to see if a larger study is feasible, not yet to prove the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Colchicine (0.5 mg daily for 180 days)
What this could lead to
If it works, this could point toward a simple, affordable way to prevent long-term leg pain and swelling after a blood clot.
What could go wrong
This is a small pilot trial focused on feasibility, not yet on proving effectiveness. Colchicine can cause diarrhea and other side effects, and it may not reduce post-thrombotic syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre de recherche du Centre hospitalier de l'Université de Montréal
RECRUITINGMontreal, Quebec, H2X 0A9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Ottawa Hospital General Campus
RECRUITINGOttawa, Ontario, K1H 8L6, Canada
Contact
Contact Email: •••••@•••••
-
The Sir Mortimer B. Davis Jewish General Hospital
NOT_YET_RECRUITINGMontreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact